Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Intensity-Modulated Radiation Therapy: Undergo IMRT
Quality-of-Life Assessment: Ancillary studies
Questionnaire Administration: Ancillary studies
Stereotactic Body Radiation Therapy: Undergo SBRT
Study summary
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.
Eligibility
Primary outcome measure(s)
- Number of Participants With a Decline of ≥4 Points in the EPIC-26 Bowel Domain (Minimal Clinically Important Difference) at Two Years — Baseline and two years
The Expanded Prostate Cancer Index Composite-26 (EPIC-26) measures health-related quality of life in men with prostate cancer across urinary incontinence, urinary irritative/obstructive, bowel, sexual, and hormonal domains. Possible scores range from 0 to 100, with higher scores indicating better quality of life. Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate decline. - Number of Participants With a Decline of ≥5 Points in the EPIC-26 Urinary Irritation Domain (Minimal Clinically Important Difference) at Two Years — Baseline and two years
The Expanded Prostate Cancer Index Composite-26 (EPIC-26) measures health-related quality of life in men with prostate cancer across urinary incontinence, urinary irritative/obstructive, bowel, sexual, and hormonal domains. Possible scores range from 0 to 100, with higher scores indicating better quality of life. Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate decline. - Percentage of Participants Alive Without Disease (Disease-free Survival [DSF]) — Randomization to biochemical failure, local failure, regional failure, distant metastasis, death, or last follow-up, whichever occurs first. Median follow-up at time of analysis was 3.2 years. Two-year estimates are reported.
Disease is defined as biochemical failure (Phoenix definition), local failure, regional failure, distant metastasis, or death from any cause. Disease-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
Trial sites (293)
| Facility | City | Region | Status |
|---|---|---|---|
| Mobile Infirmary Medical Center | Mobile | Alabama | |
| Lewis and Faye Manderson Cancer Center | Tuscaloosa | Alabama | |
| Arizona Center for Cancer Care - Gilbert | Gilbert | Arizona | |
| Arizona Center for Cancer Care-Peoria | Peoria | Arizona | |
| Arizona Center for Cancer Care - Scottsdale | Scottsdale | Arizona | |
| Arizona Center for Cancer Care-Surprise | Surprise | Arizona | |
| Arizona Oncology Associates-West Orange Grove | Tucson | Arizona | |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | |
| Kaiser Permanente-Anaheim | Anaheim | California | |
| Alta Bates Summit Medical Center-Herrick Campus | Berkeley | California | |
| Mercy Cancer Center - Carmichael | Carmichael | California | |
| Mercy San Juan Medical Center | Carmichael | California | |
| Kaiser Permanente Dublin | Dublin | California | |
| Mercy Cancer Center - Elk Grove | Elk Grove | California | |
| Fresno Cancer Center | Fresno | California | |
| Marin General Hospital | Greenbrae | California | |
| UC San Diego Moores Cancer Center | La Jolla | California | |
| Kaiser Permanente Los Angeles Medical Center | Los Angeles | California | |
| Los Angeles General Medical Center | Los Angeles | California | |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | |
| Memorial Medical Center | Modesto | California | |
| Kaiser Permanente Oakland-Broadway | Oakland | California | |
| Saint Joseph Hospital - Orange | Orange | California | |
| Stanford Cancer Institute Palo Alto | Palo Alto | California | |
| Kaiser Permanente-Rancho Cordova Cancer Center | Rancho Cordova | California | |
| Mercy Cancer Center - Rocklin | Rocklin | California | |
| Rohnert Park Cancer Center | Rohnert Park | California | |
| The Permanente Medical Group-Roseville Radiation Oncology | Roseville | California | |
| Mercy Cancer Center - Sacramento | Sacramento | California | |
| Sutter Medical Center Sacramento | Sacramento | California | |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | |
| Salinas Valley Memorial | Salinas | California | |
| Stanford Cancer Center South Bay | San Jose | California | |
| Kaiser Permanente Medical Center - Santa Clara | Santa Clara | California | |
| Kaiser Permanente Cancer Treatment Center | South San Francisco | California | |
| Gene Upshaw Memorial Tahoe Forest Cancer Center | Truckee | California | |
| Woodland Memorial Hospital | Woodland | California | |
| UCHealth University of Colorado Hospital | Aurora | Colorado | |
| UCHealth Memorial Hospital Central | Colorado Springs | Colorado | |
| Memorial Hospital North | Colorado Springs | Colorado |
+ 253 more sites — see the full list on the official registry below.
More NRG Oncology trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03367702 on ClinicalTrials.gov ↗ ← All trials in Canada